62 related articles for article (PubMed ID: 7448321)
1. Plasma levels of cyclophosphamide in patients under polychemotherapeutic regimens.
Ottolenghi L; Morasca L; Marsoni S; Piazza E; Soresi E; Libretti A; Garattini S
Biomedicine; 1980 Oct; 32(3):123-7. PubMed ID: 7448321
[TBL] [Abstract][Full Text] [Related]
2. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
Bottomley A; Biganzoli L; Cufer T; Coleman RE; Coens C; Efficace F; Calvert HA; Gamucci T; Twelves C; Fargeot P; Piccart M;
J Clin Oncol; 2004 Jul; 22(13):2576-86. PubMed ID: 15226325
[TBL] [Abstract][Full Text] [Related]
3. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
[TBL] [Abstract][Full Text] [Related]
4. High-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized trial.
Pannuti F; Lelli G; Casadio M; Piana E; Di Marco AR
Cancer Treat Rep; 1980; 64(10-11):1131-4. PubMed ID: 7459899
[TBL] [Abstract][Full Text] [Related]
5. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
6. [Polychemotherapeutic treatment of pulmonary neoplasms].
Dorigoni A; Peris GC; Scarponi F; Alcozer G
G Pneumol; 1970 Jun; 14(3):164-92. PubMed ID: 5526216
[No Abstract] [Full Text] [Related]
7. Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer.
Russo R; Bartosek I; Piazza E; Santi AM; Libretti A; Garattini S
Cancer Treat Rep; 1981; 65(7-8):555-62. PubMed ID: 7248980
[TBL] [Abstract][Full Text] [Related]
8. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics.
Cagnoni PJ; Matthes S; Day TC; Bearman SI; Shpall EJ; Jones RB
Bone Marrow Transplant; 1999 Jul; 24(1):1-4. PubMed ID: 10435726
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of small-cell bronchogenic carcinoma with a combination of chemotherapy and irradiation (author's transl)].
Dundalek E
Prax Klin Pneumol; 1980 Dec; 34(12):719-23. PubMed ID: 7465532
[No Abstract] [Full Text] [Related]
10. Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.
Piazza E; Donelli MG; Broggini M; Sessa C; Natale N; Ottolenghi L; Marsoni S; Libretti A; Mangioni C; Morasca L
Cancer Treat Rep; 1980; 64(8-9):845-54. PubMed ID: 7448822
[TBL] [Abstract][Full Text] [Related]
11. PLasma half-life and urinary excretion of cyclophosphamide in children.
Sladek NE; Priest J; Doeden D; Mirocha CJ; Pathre S; Krivit W
Cancer Treat Rep; 1980; 64(10-11):1061-6. PubMed ID: 7459891
[TBL] [Abstract][Full Text] [Related]
12. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
[TBL] [Abstract][Full Text] [Related]
13. [Parameters of cellular immunity in lung cancer patients with different types of adaptation reactions during polychemotherapy].
Stakheeva MN; Dizer IA; Smol'ianinov ES; Goldberg VE; Novitskiĭ EV; Sherstoboev EIu; Khlusova MIu
Vopr Onkol; 1998; 44(2):164-6. PubMed ID: 9615819
[TBL] [Abstract][Full Text] [Related]
14. The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma.
Afsharian P; Möllgård L; Hassan Z; Xie H; Kimby E; Hassan M
Eur J Haematol; 2005 Sep; 75(3):206-11. PubMed ID: 16104876
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
16. [The adriblastin-methotrexate combination in inoperable lung tumors].
Rimoldi R
G Ital Chemioter; 1975; 22(1-2):9-10. PubMed ID: 1235360
[No Abstract] [Full Text] [Related]
17. [Comparison of two cyclophosphamide treatment regimens in nephrotic patients with chronic glomerulonephritis].
Krasnova TN; Shilov EM; Tareeva IE; Gordovskaia NB; Lavrova ON; Miroshnichenko NG; Troepol'skaia OV; Ivanova LV; Ivanov AA
Ter Arkh; 1998; 70(6):14-7. PubMed ID: 9695216
[TBL] [Abstract][Full Text] [Related]
18. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
[TBL] [Abstract][Full Text] [Related]
19. [Results of a study on fatigue in breast cancer patients receiving adjuvant chemotherapy: the first four days after treatment are the worst].
de Jong N; Kester AD; Schouten HC; Abu-Saad HH; Courtens AM
Pflege Z; 2007 Nov; 60(11):620-5. PubMed ID: 18062627
[TBL] [Abstract][Full Text] [Related]
20. Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients.
Liu JJ; Kestell P; Findlay M; Riley G; Ackland S; Simpson A; Isaacs R; McKeage MJ
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):677-82. PubMed ID: 15554907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
